▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #975 by analyst upside · 2026-09-26
FDMT
4D Molecular Therapeutics, Inc.
Healthcare · Market Cap $799M · P/E 0x
ANALYST PRICE TARGET
+92.2%
implied upside to consensus target
Current Price $14.47
Consensus Target $27.82
Bull Target $37.0
Bear Target $18.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
8
Hold
1
Sell
0
52-Week Low $6.96
52-Week High $16.93
YTD Return +97.7%
FUNDAMENTALS
Market Cap $799M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.63
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $92M
Profit Margin -194.7%
52-WEEK RANGE
52-Week Low $6.96
52-Week High $16.93
Current Price $14.47
Bear Target $18.0
Bull Target $37.0
● Now $14.47 ● Target $27.82
TRADING DATA
Avg Volume 938K
YTD Return +97.7%
Analyst Count 11
Consensus Buy
Upside to Target +92.2%
Last Updated 2026-09-26

ANALYST SUMMARY

4D Molecular Therapeutics, Inc. (FDMT) is currently trading at $14.47 with a Wall Street consensus price target of $27.82, implying potential upside of 92.2% over the next 12 months. 11 analysts currently cover FDMT, with a consensus rating of Buy - 91% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $37.0, while the most cautious has a target of $18.0.

FDMT operates in the Healthcare sector with a market capitalisation of $799M. The stock is up 97.7% year-to-date and is currently trading near the upper end of its 52-week range of $6.96 – $16.93.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for FDMT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Cantor Fitzgerald ↑ Upgrade
Neutral → Overweight 2026-09-14 40% win rate (10 calls)
B. Riley Securities ● Initiated
Buy 2026-07-31 17% win rate (6 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-07-20 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-20 31% win rate (48 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-03-19 Building track record
Chardan Capital - Reiterated
Buy → Buy 2026-03-19 33% win rate (6 calls)
Barclays ● Initiated
Overweight 2026-01-28 Building track record
Chardan Capital - Reiterated
Buy → Buy 2025-12-18 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
19/30
Consensus clarity
4/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →